Sightera Biosciences

🚀 Exploring world-class translational research at IMTM🚀 Sightera had the incredible opportunity to visit the renowned Institute of Molecular and Translational Medicine, Faculty of Medicine&Dentistry, Palacky University (IMTM) in Olomouc, Czech Republic. This visit left us truly inspired and energized! We had the privilege of an in-depth tour at IMTM's different facilities, where we witnessed firsthand how translational research is conducted at its finest. Their approach integrates cutting-edge experimental medicine within a clinical environment, situated alongside the University Hospital in Olomouc. This close collaboration between science and clinical applications sets a gold standard for excellence in translational research. We extend our heartfelt gratitude to all IMTM colleagues and with their ongoing international research collaborations, with a special thanks to Dr. Martin Ondra, Drs. Charissa Witters and to the director of IMTM Prof. Dr. Marian Hajduch for their exceptional hospitality and interesting open discussions. We were truly honored to have engaged in such meaningful and inspiring setting. Even more exciting, we have initiated discussions about a potential partnership with IMTM. Together, we aim to push the boundaries of innovation in translational medicine and experimental research, with a shared commitment to advancing patient-centric research and developing novel potential therapies.💡🔬 #Collaboration #AIDrugDiscovery #DrugDevelopment #Innovation #Ecosystems #TranslationalResearch #Partnerships #SighteraBiosciences University of Antwerp, UAntwerpen Valorisation Office, Vlerick Business School, Institute of Molecular and Translational Medicine, Faculty of Medicine&Dentistry, Palacky University, Wetenschapspark Universiteit Antwerpen, UZA

🚀 We are thrilled to announce that our young biotech company, Sightera Biosciences, has been awarded first place in the prestigious Vlerick Student Entrepreneurship Fund 🚀 This recognition not only validates our vision but also provides us with the invaluable support and network of Vlerick Business School. This milestone comes at an exciting time, as we advance our AI-driven drug discovery platform to identify novel innovative therapies with real patient impact. A big thank you to Vlerick Business School, its alumni and donors for supporting student entrepreneurs achieving their aspirations. A big shout-out to the jury for their trust in our team, mission and concept. Mark Vandecruys, Frank Maene, Pieterjan Bouten, Marion Debruyne (she/her) Hans Vanoorbeek, Sophie Manigart, Yannick Dillen, Hans Crijns, Sylien Kesteleyn, Eline Debuyserie, Alexandre Segers. Looking forward to where our AI-driven drug discovery journey will bring us!! #AIdrugdiscovery #Smallmolecules #patientcentricmodels #Oncology #Regenerativemedicine #startup

🎤 At yesterday’s Science for health event, Maxim Le Compte took the stage to share insights on AI-powered drug discovery! As CSO of Sightera Biosciences, a spin-off project from UAntwerp and UZA, he explained how Sightera leverages data on the biological activity of known molecules to train AI and machine learning models, with a focus on oncology and regenerative medicine. Maxim was joined by his team members, Prof. Christophe Deben (CDO) and Hendrik Vercammen (CEO), who were present to further showcase their project at the event. Based in Wetenschapspark Universiteit Antwerpen, Sightera combines advanced AI with patient-relevant models to accelerate traditional drug development, aiming to create safer, more effective therapies right from the start of the discovery process. Thanks to Science for health, MEDVIA, and Rita Prota for the platform to showcase this inspiring work. Discover more about Sightera’s mission on their website 👉 https://lnkd.in/e9izdm9V

📯Joining us for our afternoon Drug Discovery & Development breakout session is Maxim Le Compte, who will be sharing his experience with his AI-powered drug discovery models! Maxim is a co-founder of Sightera Biosciences, a young spin-out from the University of Antwerp. Sightera uses data from the biological activity of known molecules to train machine learning and AI models to design new drug molecules, as well as perform in silico screening. 💊They have been focusing their efforts on #oncology and #regenerative medicine. 🫀 ✨𝗢𝗻𝗹𝘆 𝗢𝗡𝗘 𝗪𝗘𝗘𝗞 𝘁𝗼 𝗴𝗼! ✨Don’t miss out on Maxim’s talk and Science for Health’s other informative and inspiring sessions. Get your tickets today! 👇   📆12 November 2024 📍SQUARE, Brussels ✍️Info and registration: https://lnkd.in/gQpHPQ9 #sfh2024 #AI #bigdata #digitalhealth #healthinnovation #healthtech #medtech #biotech MEDVIA BioWin HST Group - Health, Science and Technology Group Johnson & Johnson Pfizer UCB GSK KU Leuven Ghent University flanders.bio imec University of Antwerp VIB Université catholique de Louvain ULB Hasselt University University of Liège Université de Namur UMONS

Sightera has been featured in a new article published by TrialSite News! 🙌 This recognition highlights our innovative approach to AI-driven drug discovery and our commitment to developing patient-relevant therapies 💊. A huge thank you to TrialSiteNews for covering our work! Stay tuned for more updates and check it out in the link below! University of Antwerp, UZA, UAntwerpen Valorisation Office, Wetenschapspark Universiteit Antwerpen Maxim Le Compte Christophe Deben Hendrik Vercammen https://lnkd.in/e7UNryqy

Sightera Biosciences visited BiotechX Europe in Basel! 🚀 We had the opportunity to showcase our technology and products at BiotechX Europe in Basel with our very first start-up booth. It was an incredible opportunity to learn from industry leaders and connect with fellow AI experts in pharma. A big thank you to everyone who visited our booth and shared their insights. We look forward to continuing our incredible journey to further innovate in the biotech industry. Maxim Le Compte Christophe Deben Hendrik Vercammen BioTechX University of Antwerp UAntwerpen Valorisation Office UZA Wetenschapspark Universiteit Antwerpen